Stocktoria
Pelthos Therapeutics Inc. PTHS
Pelthos Therapeutics Inc. (PTHS) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $16.8M at a -257.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.21 |
| Retained earnings / assets | -0.497 |
| EBIT / assets | -0.249 |
| Equity / liabilities | 0.425 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PTHS | Pelthos Therapeutics Inc. | 4/9 | -1.47 | — | — |
| RLAY | Relay Therapeutics, Inc. | 3/9 | 2.96 | — | +53.4% |
| LCTX | Lineage Cell Therapeutics, Inc. | 3/9 | -12.25 | — | — |
| LENZ | LENZ Therapeutics, Inc. | 2/9 | 15.45 | — | — |
| ALEC | Alector, Inc. | 1/9 | -9.85 | — | -79.1% |
| ELUT | ELUTIA INC. | 4/9 | -8.05 | 0.8 | -15% |
| CRBU | Caribou Biosciences, Inc. | 2/9 | -9.88 | — | — |
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
FAQ
Is PTHS financially healthy?
Pelthos Therapeutics Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does PTHS pay a dividend?
No, Pelthos Therapeutics Inc. does not currently pay a dividend.
How profitable is PTHS?
In FY2025, Pelthos Therapeutics Inc. had a net margin of -257.9% and a return on equity of -111.4%.
What is the analyst price target for PTHS?
The average Wall-Street price target for Pelthos Therapeutics Inc. is $57.71, about 160.1% above the recent price, from 7 analysts (consensus: strong buy).
Is PTHS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Pelthos Therapeutics Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.